Coming Off Ozempic: What Happens and How to Keep the Weight Off

Why

Why Weight Comes Back After Stopping

Obesity is a chronic, relapsing disease. GLP-1 medications treat it by changing how the brain regulates appetite and satiety — they do not permanently reset the body's defended fat-mass set point. When the medication stops, the appetite and satiety signaling returns toward its prior state, and most patients eat more than they intend to.

Two additional factors compound the regain: lower lean mass after weight loss (which lowers resting metabolic rate), and physiologic adaptations to weight loss that increase hunger and decrease energy expenditure for years after the loss. These adaptations are real, well-documented, and not a failure of willpower.

Evidence

What the Research Shows: STEP Withdrawal Data

The STEP 1 extension data are the cleanest evidence. Patients who lost meaningful weight on semaglutide for 68 weeks and then stopped the medication regained approximately two-thirds of the lost weight within a year, with cardiometabolic improvements reverting in parallel.

STEP 4 examined the opposite question — patients randomized to continued semaglutide vs. placebo after the loss phase — and showed continued loss in those staying on therapy versus regain in those switched to placebo.

The pattern is consistent across GLP-1 trials: discontinuation produces regain; continuation produces maintenance.

Tapering

How to Taper — When and How

Abrupt discontinuation is rarely the best plan. A typical taper:

• ·Step down one dose level every 4–8 weeks rather than stopping at the top dose.
• ·Use the lower doses to learn what your appetite and intake look like with less GLP-1 effect, while still having some medication on board.
• ·Pair each dose drop with a recheck of weight, body composition, and food logs to identify regain patterns early.
• ·For some patients, the right end state is not zero — it is a maintenance dose held indefinitely.

Maintenance

Building a Maintenance Plan

A maintenance plan that works has the same components whether the patient stays on a low dose or comes off entirely:

• ·Protein-forward nutrition (1.0–1.4 g/kg/day) and predictable meal timing.
• ·Resistance training 2–4 times per week to preserve the muscle that protects metabolic rate.
• ·Daily steps and cardiovascular work for adherence and metabolic flexibility, not as the primary weight tool.
• ·Weekly weights or trends, not daily, with a re-intervention threshold (e.g., 5 pounds regain triggers a check-in).
• ·A defined plan for what to do if regain begins — usually returning to a low maintenance GLP-1 dose before significant ground is lost.

Supervision

The Role of Physician Supervision

Discontinuation is the highest-risk transition in a weight-loss program. Most regain happens in the first 6–12 months off therapy, and most of that is preventable with structured follow-up.

A physician-supervised off-ramp adds: monthly to quarterly visits for the first year, body composition tracking to distinguish fat regain from muscle gain, and clear criteria for restarting medication. This is the difference between losing weight and keeping it off.

When to stay on

When Staying On Is the Right Call

GLP-1s were studied and approved as long-term therapies for a chronic disease. Staying on is appropriate when the patient still meets the indication, the medication is tolerated, the metabolic gains are meaningful, and discontinuation predictably produces regain.

This is the same standard as antihypertensives or statins: we do not ask “when will I get off my blood pressure medication?” as a default. For many patients with obesity, lifelong therapy at the lowest effective dose is the right answer.